"Ecstasy" (MDMA): Pharmacology, toxicology, and management of intoxication;"Ecstasy" (MDMA): Pharmakologie, toxikologie und bhandlung der akuten intoxikation

Deutsche Medizinische Wochenschrift

Volumn 128, Issue 24, 2003, Pages 1361-1366

  Liechti, Matthias E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; 4 METHOXYAMPHETAMINE; AMPHETAMINE DERIVATIVE; BROLAMFETAMINE; ILLICIT DRUG; METHAMPHETAMINE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; PHENETHYLAMINE;

CARDIOVASCULAR EFFECT; DRUG INTOXICATION; HUMAN; NEUROLOGICAL COMPLICATION; NEUROPHARMACOLOGY; NEUROTOXICOLOGY; REVIEW; SUBSTANCE ABUSE;

HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POISONING; STREET DRUGS;

EID: 0038199863     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-39975     Document Type: Review

References (47)

1. Baggott M, Stuart R, Jerome L. Medical emergencies and adverse events in ecstasy users. Multidiscipliary Association for Psychodelic Studies (www.maps.org), In: Baggott M, Jerome L, Stuart R, editors. 3,4-Methylenedioxymethamphetamine (MDMA): A review of the English-language scientific and medical literature. 2001: 147-185
2. Baggott M, Stuart R, Jerome L. Medical emergencies and adverse events in ecstasy users. Multidiscipliary Association for Psychodelic Studies (www.maps.org), In: Baggott M, Jerome L, Stuart R, editors. 3,4-Methylenedioxymethamphetamine (MDMA): A review of the English-language scientific and medical literature. 2001: 147-185
3. Benz R, Iten PX, Schmid M, Vogt M. Ein fremdes weisses Pulver. Schweiz Med Forum 2002; 2: 475-476
4. Boot BP, McGregor IS, Hall W. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 2000; 355: 1818-1821
5. Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 2002; 97: 1531-1536
6. De la Torre R, Farré M, Roset PN et al. Pharmacology of MDMA in humans. Ann N Y Acad Sci 2000; 914: 225-237
7. Dughiero G, Schifano F, Forza G. Personality dimensions and psychopathological profiles of Ecstasy users. Hum Psychopharmacol Clin Exp 2001; 16: 635-639
8. Gamma A, Liechti ME. The psychophysiology of substance-related disorders. London: Wiley, In: D'haenen H, Den Boer JA, Willner P, editors. Biological Psychiatry. 2002: 467-493
9. Giroud C, Augsburger M, Sadeghipour F, Varesio E, Veuthey J-L, Rivier L. Ecstasy - la situation en Suisse romande. Composition des saisies, analyse des échantillons biologiques et brève revue de son action pharmacologique et de sa toxicité. Schweiz Rundsch Med Prax 1997; 86: 510-523
10. Gledhill JA, Moore DF, Bell D, Henry JA. Subarachnoidal haemorrhage associated with MDMA abuse. J Neurol Neurosurg Psychiat 1993; 56: 1036-1037
11. Gouzoulis-Mayfrank E, Daumann J, Sass H. Neurotoxische Langzeitschäden bei Ecstasy (MDMA)-Konsumenten: Überblick über den aktuellen Wissensstand. Nervenarzt 2002; 73: 405-421
12. Gouzoulis-Mayfrank E, Hermle L, Kovar K-A, Sass H. Die entaktogene "Ecstasy" (MDMA), "Eve" (MDE) und andere ringsubstituierte Methamphetaminderivate. Nervenarzt 1996; 67: 369-380
13. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Psychopharmacology 1999; 142: 41-50
14. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2002; 162: 396-405
15. Hartung TK, Schofield E, Short AI, Parr MJA, Henry JA. Hyponatriaemic states following 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy" ingestion. QJ Med 2002; 95: 431-437
16. Henry JA. Ecstasy and the dance of death. Br Med J 1992; 305: 5-6
17. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA ("Ecstasy") induces vasopressin secretion. Lancet 1998; 351: 1784
18. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998; 352: 1751-1752
19. Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992; 340: 384-387
20. Henry JA, Rella JG. Medical risks associated with MDMA use. Rochester, Vermont: Park Street Press, In: Holland J, editor. Ecstasy: the complete guide - A comprehensive look at the risks and benefits of MDMA. 2001: 71-86
21. Hernández Lopez C, Farré M, Roset PN et al. 3,4-Methylenedioxymethamphetamine (Ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol Exp Ther 2002; 300: 236-244
22. Johnston LD, O'Malley PM, Bachman JG. Monitoring the Future national survey results on drug use, 1975-2001. Volume I: Secondary school students. Bethesda, MD. National Institute on Drug Abuse, 2002; NIH Publication No. 02-5106
23. Kupferschmidt H, Wyss PA, Fattinger K, Meier-Abt PJ. Medizinische Probleme beim Konsum illegaler Drogen. Basel: Documed, In: Grundlagen der Arzneimitteltherapie. 2001
24. Lange-Brock N, Berg T, Müller AR et al. Akutes Leberversagen nach Konsum von Ecstasy (MDMA). Z Gastroenterol 2002; 40: 581-586
25. Lester SJ, Baggott M, Welm S et al. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind placebo-controlled trial. Ann Int Med 2000; 133: 969-973
26. Liechti ME, Achermann E. Das Pneumomediastinum. Dtsch Med Wochenschr 2002; 127: 2273-2276
27. Liechti ME, Baumann C, Gamma A, Vollenweider FX. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 2000; 22: 513-521
28. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology 2001; 154: 161-168
29. Liechti ME, Mathys J. Komatöses Zustandsbild bei einem 21-jährigen Partygänger. Internist 2003; 44: 215-218
30. Liechti ME, Saur M, Gamma A, Hell D, Vollenweider FX. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000; 23: 396-404
31. Liechti ME, Vollenweider FX. Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmacol 2000; 10: 289-295
32. Liechti ME, Vollenweider FX. The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ("Ecstasy") in healthy volunteers. J Psychopharmacol 2000; 14: 269-274
33. Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol Clin Exp 2001; 16: 589-598
34. Ling LH, Marchant C, Buckley NA, Prior M, Irvine RJ. Poisoning with the recreational drug paramethoxyamphetamine. Med J Aust 2001; 174: 453-455
35. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998; 352: 1433-1437
36. Meyer LV. Suchtmittelnachweis. Internist 1999; 40: 601-604
37. Milroy CM, Clark JC, Forrest ARW. Pathology of deaths associated with ecstasy and eve misuse. J Clin Pathol 1996; 49: 149-153
38. Morgan MJ. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 2000; 152: 230-248
39. Nichols DE. Differences between the mechanism of action of MDMA, MBDB, and the classical hallucinogens. Identification of a new therapeutic class: Entactogens. J Psychoactive Drugs 1986; 18: 305-313
40. Reneman L, Booij J, Reitsma JB et al. Effects of dose, sex, and longterm abstention from use of toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 2001; 358: 1864-1869
41. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science 2002; 297: 2260-2263
42. SFA/ISPA. Ecstasy in der Schweiz, die erste repräsentative Studie zur Modedroge. Lausanne: SFA (Schweizerische Fachstelle für Alkoholund andere Drogenprobleme), 1996
43. Soar K, Turner JJD, Parrott AC. Psychiatric disorders in Ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history. Hum Psychopharmacol Clin Exp 2001; 16: 641-645
44. Vastag B. Ecstasy experts want realistic messages. J Am Med Assoc 2001; 286: 777
45. Verheyden SL, Hadfield J, Calin T, Curran HV. Sub-acute effects of MDMA (±3,4-methylenedioxymethamphetamine, "ecstasy") on mood: evidence of gender differences. Psychopharmacology 2002; 161: 23-31
46. von Sydow K, Lieb R, Pfister H, Höfler M, Wittchen H-U. Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults-a transient phenomenon? Results of a longitudinal community study. Drug Alcohol Depend 2002; 66: 147-159
47. Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A. "Saturday night fever": ecstasy related problems in a London accident and emergency department. J Accid Emerg Med 1998; 15: 322-367